Physician profile
Ishwaree R Chogle
NPI 1871934778
$3,109.48
in general payments reported to CMS, 2019-2025
28 companies · $1,238 in 2025
The $1,238 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $124 · 2023: $678 · 2024: $1,070 · 2025: $1,238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,917 · Education: $68.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,916.82 |
| Education | $68.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $583.95 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $267.34 | 2022-2025 | Jardiance, Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $265.54 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $263.80 | 2023-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $228.14 | 2023-2025 | Rexulti |
| Astellas Pharma US INC | $221.75 | 2023-2025 | Veozah |
| Glaxosmithkline, LLC. | $190.34 | 2024-2025 | Trelegy Ellipta, Penmenvy, Rotarix |
| Pfizer INC. | $149.52 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $148.76 | 2022-2025 | Trintellix |
| Amgen INC. | $127.73 | 2023-2025 | Repatha, Repatha, Otezla |
| Abbvie INC. | $118.78 | 2023-2025 | Qulipta |
| Ironwood Pharmaceuticals, INC | $76.48 | 2023-2024 | Linzess |
| Kowa Pharmaceuticals America, INC. | $72.30 | 2023-2025 | Seglentis, Zoryve, Livalo |
| Exact Sciences Corporation | $59.78 | 2023-2024 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $44.90 | 2023-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $40.98 | 2024 | Rexulti |
| Sobi, INC | $29.17 | 2022 | |
| Abbott Laboratories | $27.93 | 2024 | Freestyle Libre 3 |
| Dynavax Technologies Corporation | $24.91 | 2023 | Heplisav-B |
| Hologic Sales and Service, LLC | $23.81 | 2025 | Thinprep 2000 Processor |
| Merck Sharp & Dohme LLC | $22.25 | 2023 | Belsomra |
| Cranial Technologies, INC | $20.02 | 2022 | |
| Kaleo, INC. | $19.93 | 2022 | |
| Inspire Medical Systems, INC. | $19.89 | 2025 | Inspire |
| Organon LLC | $16.42 | 2023 | Nexplanon |
| Esperion Therapeutics, INC. | $16.30 | 2024 | Nexletol |
| Phathom Pharmaceuticals, INC. | $14.68 | 2024 | Voquezna |
| Dexcom, INC. | $14.08 | 2024 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ishwaree Chogle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.